A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Phase 2 Completed 26 enrolled Supernus Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD).

Timeline

Start: 2020-12-07
Primary completion: 2021-09-28
Completion: 2021-09-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dalzanemdor	Small molecule	3 mg	Oral

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Summary

Timeline

Drugs

Indications